Related Experiment Video
Updated: Aug 14, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Richard H Baltz1, Vivian Miao, Stephen K Wrigley
1Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA. rbaltz@cubist.com
Abstract:
Daptomycin (Cubicin) is a lipopeptide antibiotic approved in the USA in 2003 for the treatment of skin and skin structure infections caused by Gram-positive pathogens. It is a member of the 10-membered cyclic lipopeptide family of antibiotics that includes A54145, calcium-dependent antibiotic (CDA), amphomycin, friulimicin, laspartomycin, and others. This review highlights research on this class of antibiotics from 1953 to 2005, focusing on more recent studies with particular emphasis on the interplay between structural features and antibacterial activities; chemical modifications to improve activity; the genetic organization and biosynthesis of lipopeptides; and the genetic engineering of the daptomycin biosynthetic pathway to produce novel derivatives for further chemical modification to develop candidates for clinical evaluation.
More Related Videos
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Detergent Purification of Membrane Proteins
Antifungal Agents

